va

Retinyl acetate (Vitamin A acetate) is a group of unsaturated nutritional hydrocarbons, that contains retinal, retinol, retinoic acid, and several provitamins A carotenoids, among which beta-carotene is the most important.

β-Carotene (Provitamin A) is a naturally-occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities. As an anti-oxidant, beta carotene inhibits free-radical damage to DNA.

VA-K-14 hydrochloride(VAK14 HCl) is a selective thyrotropin receptor (TSHR) antagonist (IC50= 12.3 μM) that inhibits TSHR stimulation by serum and monoclonal TSHR-stimulating antibodies from patients with GD and abrogates TSHR signaling.

DBCO-PEG4-VA-PBD is a cleavable 4-unit PEG ADC linker utilized in antibody-drug conjugate (ADC) synthesis [1].

Mal-PEG4-VA, a noncleavable ADC linker featuring a Maleimide group, is utilized in the synthesis of antibody-drug conjugates.

MC-VA-PAB-PNP is a cleavable ADC linker that can be used for the synthesis of antibody-conjugated active molecules (ADCs).

Mal-PEG8-VA-PAB-PNP is a degradable, hydrophilic linker that can be used in the synthesis of ADCs.

Fmoc-VA-PAB-PNP is a cleavable linker with an Fmoc protecting group, which can be used in the synthesis of ADCs.

MC-VA-PAB-MMAD is a thiol-reactive Drug-linker. MMAD is an effective microtubule (tubulin) inhibitor, which is commonly used in the synthesis of antibody-drug conjugates (ADCs).

MC-VA-PAB-Exatecan is a part of the antibody-conjugated active molecule ADC. MC-VA-PAB-Exatecan is formed by coupling the cleavable ADC linker MC-VA-PAB with the payload Exatecan and is therefore used in antibody–drug conjugate development research systems. MC-VA-PAB-Exatecan is applied in ADC design studies to evaluate linker stability, payload release kinetics, and targeted cytotoxic delivery mechanisms in cancer cell models.

VA-PAB-DMEA-PNU159682 is a transpeptidase reaction-type Drug-linker with an innovative highly stable and degradable linker. PNU159682 is a DNA topoisomerase II (Topo II) inhibitor with excellent cytotoxicity and can be used in the synthesis of antibody-drug conjugates (ADCs).

MC-PEG2-VA-PAB-Exatecan (Compound DL-18) is a drug-linker conjugate designed for use in antibody-drug conjugates (ADC). It consists of Exatecan and a linker. This compound is utilized in the synthesis of ADCs.

DBCO-PEG4-VA-PABC-MMAE is a drug-linker conjugate for ADCs, consisting of a tubulin inhibitor (MMAE) and a cleavable linker (DBCO-PEG4-VA-PABC). This compound is applicable for synthesizing ADCs.

BCN-HS-PEG2-VA-PABC is an ADC linker used in the synthesis of PL1601.

DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate for ADC (antibody-drug conjugate) that features a SG3199-based DNA minor groove cross-linking agent and a cleavable linker. This compound is suitable for the synthesis of ADCs.

VA5 is an transamidase inhibitor by direct binding at the transamidase site. VA5 also inhibits GTP-binding activities. It interaction at the transamidase site locks the protein in the extended/open conformation to disorganize/inactivate the GTP binding/GT

MC-VA-PABC-MMAE is a conjugate composed of the ADC linker peptide MC-VA-PABC and the cytotoxic agent monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization [1] [2]. It functions as an agent-linker module for antibody-drug conjugates (ADCs).

SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells. This compound undergoes in situ conversion to active PROTAC via a copper-catalyzed click reaction utilizing endogenous copper present in tumor tissues. Additionally, SA-VA induces apoptosis and arrests cell cycle progression in the S phase [1].

Aristolochic acid Va, a natural compound, is isolated from Aristolochia plants [1].

BCN-HS-PEG2-VA-PABC-SG3199 (Compound 4) functions as a pyrrolobenzodiazepine-based agent linker for antibody-drug conjugates (ADC) [1]. This compound also serves as a click chemistry reagent, featuring a BCN group capable of participating in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules.

Mal-va-mac-SN38 is a conjugate molecule functioning as an ADC (Antibody-Drug Conjugate) drug-linker. This compound comprises the cytotoxic ADC agent SN-38 and a linker. Once inside the body, Mal-va-mac-SN38 rapidly forms a covalent bond with endogenous albumin, resulting in the formation of HSA-va-mac-SN38. It demonstrates remarkable stability in human plasma and exhibits both antitumor and antimetastatic properties.

Mix5 Va,Vd2,Vd3,Ve,Vk1(0.1%Bht) (Standard) is a reference standard of Mix5 Va,Vd2,Vd3,Ve,Vk1(0.1%Bht) intended for quantitative analysis, quality control, and related biochemical research applications.

2-MSP-5-HA-Val-Cit-PAB-Exatecan (A-24) is a drug-linker conjugate designed for use in antibody-drug conjugates (ADC). This compound consists of Exatecan and a connecting linker, and it can be applied in the synthesis of ADCs.

Mal-PEG4-VA-PBD is a commonly used linker-toxin conjugate structure in antibody-drug conjugates (ADCs). It consists of Mal for conjugation to antibody thiols, PEG4 as a hydrophilic spacer arm to improve solubility, VA as a dipeptide linker cleavable by lysosomal proteases, and a pyrrolobenzodiazepine (PBD) DNA alkylator as the cytotoxic payload. Mal-PEG4-VA-PBD is cleaved by proteases upon cell entry to release PBD, which then forms covalent adducts with DNA and induces cell death.